Canada - English - Health Canada

teva canada limited - rosiglitazone (rosiglitazone maleate) - tablet - 2mg - rosiglitazone (rosiglitazone maleate) 2mg - thiazolidinediones

Canada - English - Health Canada

teva canada limited - rosiglitazone (rosiglitazone maleate) - tablet - 4mg - rosiglitazone (rosiglitazone maleate) 4mg - thiazolidinediones

Canada - English - Health Canada

teva canada limited - rosiglitazone (rosiglitazone maleate) - tablet - 8mg - rosiglitazone (rosiglitazone maleate) 8mg - thiazolidinediones

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - rosiglitazone maleate (unii: kx2339dp44) (rosiglitazone - unii:05v02f2kdg) - rosiglitazone 2 mg - avandia is a thiazolidinedione antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. important limitations of use: risk summary limited data with avandia in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . in animal reproduction studies, no adverse developmental effects were observed when rosiglitazone was administered to pregnant rats and rabbits during organogenesis at exposures up to 4 times the maximum recommended human dose (mrhd) of 8 mg daily (see data). the estimated background risk of major birth defects is 6% to 10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20% to 25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - rosiglitazone maleate (unii: kx2339dp44) (rosiglitazone - unii:05v02f2kdg), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - rosiglitazone 2 mg - after consultation with a healthcare professional who has considered and advised the patient of the risks and benefits of rosiglitazone, avandamet® is indicated as an adjunct to diet and exercise to improve glycemic control when treatment with both rosiglitazone and metformin is appropriate in adults with type 2 diabetes mellitus who either are: - already taking rosiglitazone, or - not already taking rosiglitazone and unable to achieve glycemic control on other diabetes medications and, in consultation with their healthcare provider, have decided not to take pioglitazone (actos® ) or pioglitazone-containing products (actoplus met® , actoplus met xr® , duetact® ) for medical reasons. - due to its mechanism of action, rosiglitazone is active only in the presence of endogenous insulin. therefore, avandamet should not be used in patients with type 1 diabetes. - coadministration of avandamet with insulin is not recommended [see warnings and precautions (5.2, 5.3)] . - initiation in patients with established new

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - rosiglitazone maleate (unii: kx2339dp44) (rosiglitazone - unii:05v02f2kdg) - rosiglitazone maleate 2 mg

Canada - English - Health Canada

pharmascience inc - rosiglitazone (rosiglitazone maleate) - tablet - 2mg - rosiglitazone (rosiglitazone maleate) 2mg - thiazolidinediones

Canada - English - Health Canada

pharmascience inc - rosiglitazone (rosiglitazone maleate) - tablet - 4mg - rosiglitazone (rosiglitazone maleate) 4mg - thiazolidinediones

Canada - English - Health Canada

pharmascience inc - rosiglitazone (rosiglitazone maleate) - tablet - 8mg - rosiglitazone (rosiglitazone maleate) 8mg - thiazolidinediones

Canada - English - Health Canada

pharmel inc - rosiglitazone (rosiglitazone maleate) - tablet - 2mg - rosiglitazone (rosiglitazone maleate) 2mg - thiazolidinediones